All In Biotech

Drug Trial Radar · NCT01119105

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection

Last checked: Nov 19, 2026Latest source record: Nov 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

May 2010

Primary completion

Dec 31, 2010

Study completion Feb 3, 2011

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
First posted
May 7, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infection.

Conditions

  • Bacterial Infections
  • Infection

Interventions

  • BC-3781Drug

    BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.

  • BC-3781Drug

    BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.

  • VancomycinDrug

    Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical ResponseTime frame: Test of Cure (TOC), 7 - 14 days post final treatment
  2. Clinical ResponseTime frame: Test of Cure (TOC), 7 - 14 days post final treatment

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • BC-3781 Study Center 002

    Chula Vista, California

  • BC-3781 Study Center 001

    La Mesa, California

  • BC-3781 Study Center 003

    Oceanside, California

  • BC-3781 Study Center 012

    Columbus, Georgia

  • BC-3781 Study Center 018

    Savannah, Georgia

  • BC-3781 Study Center 021

    Baton Rouge, Louisiana

  • BC-3781 Study Center 023

    Lafayette, Louisiana

  • BC-3781 Study Center 004

    Butte, Montana

  • BC-3781 Study Center 016

    Somers Point, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.